tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Vera Therapeutics announces anticipated upcoming milestones

Submission of a BLA for atacicept in IgAN to the U.S. FDA in Q4 2025 for accelerated approval; potential commercial launch in 2026; Presentation of the full 36-week results from the pivotal ORIGIN 3 trial expected at a medical congress in Q4 2025; Initial results from the PIONEER Phase 2 basket trial expected in Q4 2025; Pivotal ORIGIN 3 study expected to be completed in 2027

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1